Cargando…

A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice

BACKGROUND: Although the proteasome is a validated anticancer target, the clinical application of its inhibitors has been limited because of inherent systemic toxicity. To broaden clinical utility of proteasome inhibitors as anticancer agents, it is critical to develop strategies to selectively targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wehenkel, M, Ban, J-O, Ho, Y-K, Carmony, K C, Hong, J T, Kim, K B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3389428/ https://www.ncbi.nlm.nih.gov/pubmed/22677907 http://dx.doi.org/10.1038/bjc.2012.243

Ejemplares similares

Co-Inhibition of the Immunoproteasome Subunits LMP2 and LMP7 Ameliorates Immune Thrombocytopenia
por: Du, Sheng-hong, et al.
Publicado: (2021)

γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules
por: Prasad, Sahdeo, et al.
Publicado: (2016)

M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models
por: Sanderson, Michael P., et al.
Publicado: (2021)

Combination therapy with PEG-IFN-α and 5-FU inhibits HepG2 tumour cell growth in nude mice by apoptosis of p53
por: Hagiwara, S, et al.
Publicado: (2007)

Immunohistochemical Identification and Assessment of the Location of Immunoproteasome Subunits LMP2 and LMP7 in Acquired Cholesteatoma
por: Rutkowska, Justyna, et al.
Publicado: (2023)

Immunoproteasome subunit LMP7 Deficiency Improves Obesity and Metabolic Disorders
por: Kimura, Hiroaki, et al.
Publicado: (2015)

Immunoproteasome subunit ß5i/LMP7-deficiency in atherosclerosis
por: Hewing, Bernd, et al.
Publicado: (2017)

Inhibition and deficiency of the immunoproteasome subunit LMP7 suppress the development and progression of colorectal carcinoma in mice
por: Koerner, Julia, et al.
Publicado: (2017)

The Immunoproteasome Subunits LMP2, LMP7 and MECL-1 Are Crucial Along the Induction of Cerebral Toxoplasmosis
por: French, Timothy, et al.
Publicado: (2021)

MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours
por: Khandelwal, A, et al.
Publicado: (2008)

Prevention of colitis-associated cancer by selective targeting of immunoproteasome subunit LMP7
por: Vachharajani, Niyati, et al.
Publicado: (2017)

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)

The immunoproteasome subunit LMP10 mediates angiotensin II-induced retinopathy in mice
por: Wang, Shuai, et al.
Publicado: (2018)

Airway epithelial immunoproteasome subunit LMP7 protects against rhinovirus infection
por: Dimasuay, Kris Genelyn, et al.
Publicado: (2022)

Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: Involvement of CB(2)
por: Olea-Herrero, N, et al.
Publicado: (2009)

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs
por: Iwasa, T, et al.
Publicado: (2010)

Induction of the Immunoproteasome Subunit Lmp7 Links Proteostasis and Immunity in α-Synuclein Aggregation Disorders
por: Ugras, Scott, et al.
Publicado: (2018)

Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types
por: Green, S R, et al.
Publicado: (2010)

Tumour hypoxia determines the potential of combining mTOR and autophagy inhibitors to treat mammary tumours
por: Seront, E, et al.
Publicado: (2013)

Restoration of PPP2CA expression reverses epithelial-to-mesenchymal transition and suppresses prostate tumour growth and metastasis in an orthotopic mouse model
por: Bhardwaj, A, et al.
Publicado: (2014)

The role of tumour-derived iNOS in tumour progression and angiogenesis
por: Kostourou, V, et al.
Publicado: (2011)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC
por: Dean, E J, et al.
Publicado: (2010)

Enhanced progression of human prostate cancer PC3 cells induced by the microenvironment of the seminal vesicle
por: Kumano, M, et al.
Publicado: (2008)

X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary
por: Miyamoto, M, et al.
Publicado: (2014)

The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
por: Baker, L C J, et al.
Publicado: (2012)

Resistance to tumour challenge after tumour laser thermotherapy is associated with a cellular immune response
por: Ivarsson, K, et al.
Publicado: (2005)

Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model
por: Arcaroli, J J, et al.
Publicado: (2013)

COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia
por: Farooqui, M, et al.
Publicado: (2007)

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer model
por: Reed, M D, et al.
Publicado: (2013)

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
por: Dredge, K, et al.
Publicado: (2011)

Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction
por: Lickliter, J D, et al.
Publicado: (2007)

An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway
por: Chen, G, et al.
Publicado: (2014)

Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells
por: Bruynzeel, A M E, et al.
Publicado: (2007)

Antagonism between granulocytic maturation and deacetylase inhibitor-induced apoptosis in acute promyelocytic leukaemia cells
por: Hennig, D, et al.
Publicado: (2015)

Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers
por: Lee, Miseon, et al.
Publicado: (2019)

A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth
por: Li, D, et al.
Publicado: (2014)

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines
por: Wang, Y, et al.
Publicado: (2011)

Preclinical efficacy of the bioreductive alkylating agent RH1 against paediatric tumours
por: Hussein, D, et al.
Publicado: (2009)

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours
por: Campone, M, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_294i6j97h47q9beml0oqd0thpo